Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, Shanghai Xuhui District Central Hospital and Zhongshan-Xuhui Hospital, Zhongshan Hospital, Fudan University, Shanghai, China.
Department of Medicine, BestNovo (Beijing) Medical Technology Co., Ltd, Beijing, China.
J Cell Mol Med. 2020 Jun;24(12):6558-6570. doi: 10.1111/jcmm.15364. Epub 2020 May 7.
A cluster of pneumonia (COVID-19) cases have been found in Wuhan China in late December, 2019, and subsequently, a novel coronavirus with a positive stranded RNA was identified to be the aetiological virus (severe acute respiratory syndrome coronavirus 2, SARS-CoV-2), which has a phylogenetic similarity to severe acute respiratory syndrome coronavirus (SARS-CoV). SARS-CoV-2 transmits mainly through droplets and close contact and the elder or people with chronic diseases are high-risk population. People affected by SARS-CoV-2 can be asymptomatic, which brings about more difficulties to control the transmission. COVID-19 has become pandemic rapidly after onset, and so far the infected people have been above 2 000 000 and more than 130 000 died worldwide according to COVID-19 situation dashboard of World Health Organization (https://covid19.who.int). Here, we summarized the current known knowledge regarding epidemiological, pathogenesis, pathology, clinical features, comorbidities and treatment of COVID-19/ SARS-CoV-2 as reference for the prevention and control COVID-19.
2019 年 12 月下旬，中国武汉发现了一组肺炎（COVID-19）病例，随后鉴定出一种新型带有正链 RNA 的冠状病毒，为病因病毒（严重急性呼吸综合征冠状病毒 2，SARS-CoV-2），其与严重急性呼吸综合征冠状病毒（SARS-CoV）具有系统发育相似性。SARS-CoV-2 主要通过飞沫和密切接触传播，老年人或患有慢性病的人属于高危人群。受 SARS-CoV-2 影响的人可能无症状，这给控制传播带来了更大的困难。COVID-19 发病后迅速流行，根据世界卫生组织（https://covid19.who.int）的 COVID-19 情况仪表板，截至目前，全球感染人数已超过 200 万，死亡人数超过 13 万。在这里，我们总结了目前关于 COVID-19/SARS-CoV-2 的流行病学、发病机制、病理学、临床特征、合并症和治疗的已知知识，以供 COVID-19 的预防和控制参考。
